Masimo Root Wins the GOLD 2015 Medical Design Excellence Award

June 9, 2015

IRVINE, CA -- (Marketwired) -- 06/09/15 -- Masimo (NASDAQ: MASI) announced today that its Root® patient monitoring and connectivity platform has received the GOLD 2015 Medical Design Excellence Award -- the highest award given in the general hospital devices and therapeutic products category. The 2015 Medical Design Excellence Award winners were honored today at a presentation ceremony in New York City'sJacob K. Javits Convention Center, in conjunction with the Medical Design & Manufacturing (MD&M) East Conference and Exposition (

Root comes with a dock for the Radical-7® handheld monitor or Radius-7® wearable monitor, an intuitive display, and multiple networking/connectivity options. Root integrates multiple streams of data on an easy-to-read, touch-screen.

Root innovations include:

  • MOC-9™ - Flexible measurement expansion through Masimo Open Connect™ (MOC-9™) with MOC-9 modules from Masimo or third-party measurement by other companies to expand the platform's measurements and capabilities. New MOC-9 modules in the U.S. will require new 510(k) clearances
  • ISA™ Capnography - CO2 sidestream module featuring fast warm-up time and the innovative and cost-effective Nomoline™ sampling line
  • SedLine® brain function monitoring module, which provides four channels of EEG to help clinicians better understand the effects of anesthesia on the brain
  • Iris™ connectivity gateway designed to provide integration for standalone devices such as IV pumps, ventilators, hospital beds, and other patient monitors. Iris enables Root to intake data from all devices connected to the patient, acting as an in-room patient monitor and connectivity hub. Alarms and alerts for all devices are seamlessly forwarded to the patient's clinician and all device data are effortlessly documented in the patient's electronic medical record
  • Wireless functionality - Capable of transmitting information through Bluetooth and WiFi.

Root can accommodate Radical-7 or Raidus-7, the first and only wearable, wireless monitor with Masimo's breakthrough rainbow® SET® technology, to measure blood oxygenation, pulse rate, and rainbow® acoustic monitoring (RAM™) through acoustic respiration rate (RRa®). Radius-7 offers patients continuous monitoring while providing freedom of movement, allowing hospitals to optimize capacity by getting patients out of bed faster. Studies have shown that patient mobility is a key factor in more rapid patient recovery.1

The Medical Design Excellence Awards competition ( is organized and presented by UBM Canon and is the only awards program that exclusively recognizes contributions and advances in the design of medical products. Entries are evaluated on the basis of their design and engineering features, including innovative use of materials, user-related functions that improve healthcare delivery and change traditional medical attitudes or practices, features that provide enhanced benefits to the patient, and the ability of the product development team to overcome design and engineering challenges so that the product meets its clinical objectives. A comprehensive review of the entries was performed by an impartial, multidisciplinary panel of third-party jurors with expertise in biomedical engineering, human factors, industrial design, medicine, and diagnostics.

"We are honored to have Root receive the GOLD MDEA-winning product," said Joe Kiani, Founder and CEO of Masimo. "We hope Root will eliminate barriers to entry for innovative products and barriers to interoperability and help automate patient care with its open and scalable architecture."

1 Needham D, Korupolu R, Zanni J, Pradhan P, Colantuoni E, Palmer J, Brower R, Fan E. "Early Physical Medicine and Rehabilitation for Patients With Acute Respiratory Failure: A Quality Improvement Project." Archives of Physical Medicine and Rehabilitation Vol 91, Issue 4, PP 536-542, April 2010

About Masimo
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care-helping solve "unsolvable" problems. In 1995, the company debuted Measure-through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 indepensdent and objective studies have shown that Masimo SET® outperforms other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). Additional information about Masimo and its products may be found at @masimoinnovates

Forward-Looking Statements
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI are trademarks or registered trademarks of Masimo.

Media Contact:
Mike Drummond
(949) 297-7434

Source: Masimo